Knight Therapeutics (GUD) Q2 2025 earnings summary

Executive summary

• Achieved record-high adjusted revenues of CAD 197 million for H1 2025, with 15% organic growth on a constant currency basis driven by promoted products and major portfolio expansions, including over 50 products from Paladin and Sumitomo transactions.

• Expanded agreements with Helsinn and Incyte, adding innovative oncology products and advancing regulatory submissions and approvals in key markets.

• Net loss widened to CAD 12.6 million in Q2, mainly from mark-to-market revaluations and higher costs, with an operating loss of CAD 3.7 million.

Financial highlights

• Q2 2025 revenues reached CAD 108.5 million, up 15% year-over-year; constant currency growth was 21%.

• Adjusted EBITDA for Q2 2025 was CAD 15.5 million (CAD 0.16 per share), relatively unchanged year-over-year.

• Gross margin was CAD 49 million (46% of adjusted revenue), down from 48% due to product mix and hyperinflation accounting in Argentina.

• Cash inflow from operations was CAD 20.3 million, compared to outflow of CAD 1.1 million prior year.

• Net debt position at quarter-end was CAD 6.5 million, with CAD 91.2 million in cash and marketable securities.

Outlook and guidance

• Fiscal 2025 revenue guidance raised to CAD 410–420 million (from CAD 390–405 million), driven by strong H1 performance, Sumitomo and Paladin transactions, and new product launches.

• EBITDA expected to remain at approximately 13% of revenues.

• Guidance assumes no material impact from hyperinflation in Argentina, no major supply disruptions, and successful product launches.

• Anticipates step-ups in EBITDA margin in 2026–2028 as new product launches scale.